Axellis Paves the Way to Becoming an International Leader in Oncology and Cardiology Technology.3 Deals Completed as Axellis Embarks on Global Expansion LONDON -- Axellis Ltd, the UK and US based medical technology company, has signalled its intent to become a leading, global provider of specialist hardware and software solutions to optimise treatments in Oncology and Cardiology cardiology Medical specialty dealing with heart diseases and disorders. It began with the 1749 publication by Jean Baptiste de Sénac of contemporary knowledge of the heart. Diagnostic methods improved in the 19th century, and in 1905 the electrocardiograph was invented. with the announcement of three significant acquisitions. The first three acquisitions completed by Axellis are part of the company's strategy to create a software solutions business with a full suite of complimentary technologies that will support and add value to today's Oncology and Cardiology programmes. The acquisitions will also enable Axellis to immediately access the buoyant US healthcare market which launches the development of its ambitious business plan. Commenting on the acquisitions and the growth potential of Axellis, Trevor Stanley, CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. said: "In making these acquisitions, Axellis has quickly and clearly established itself as an emerging leader in the provision of advanced software tools to support the oncology and cardiology sectors, as well as adding an exceptional team of founder-managers. Not only do these businesses each have significant growth potential in their own right, but they offer tremendous synergies to rapidly grow our healthcare business through the integration of the suite of proprietary software tools, patented technologies and derived medical products now available from Axellis. These systems will become the cornerstones of Axellis' patient-centred vision". Acquisitions Innocure LLC (Logical Link Control) See "LANs" under data link protocol. LLC - Logical Link Control is a US-based specialist developer of Oncology software tools and the manufacture of a new, advanced design of compensating filters used in conjunction with linear accelerators for the delivery of intensity modulated mod·u·late v. mod·u·lat·ed, mod·u·lat·ing, mod·u·lates v.tr. 1. To adjust or adapt to a certain proportion; regulate or temper. 2. radiation therapy. Three of Innocure's proprietary compensators, received FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. 510K registration in March 2006 and the company currently has approval for the reimbursement of treatments utilising the devices from both Medicare and Medicaid Medicare and Medicaid U.S. government programs in effect since 1966. Medicare covers most people 65 or older and those with long-term disabilities. Part A, a hospital insurance plan, also pays for home health visits and hospice care. centres. Dr. Donald W. Collins, founder and CTO (Chief Technical Officer) The executive responsible for the technical direction of an organization. See CIO and salary survey. of Innocure, will join the Axellis leadership team where he will contribute his deep domain expertise and extensive knowledge of the US Healthcare market. Bluescope Medical Technologies Ltd is a leading developer of non-invasive advanced cardio-pulmonary acoustic monitoring systems used to measure cardiac and respiratory sounds, in addition to the measurement and assessment of the electrical information generated by the heart. The company's latest devices under development are designed to provide more accurate diagnosis and monitoring of patients in acute critical care environments as well as in remote community settings. Dr. Peter Donnelly Peter Donnelly, FRS is an Australian mathematician and Professor of Statistical Science at the University of Oxford. He is a specialist in applied probability and has made important mathematical contributions to coalescent theory. and Andy O'Hara, who jointly built the Bluescope technology platform, and their key staff have joined Axellis and will continue to contribute comprehensive software engineering, technical and business skills to lead innovation in the Cardiology and Oncology markets. Mailling Wright Products Ltd uses digital technology to capture patient data, perform analysis in the remote design and off-site manufacture of patient-specific immobilisation n. 1. The act or process of limiting movement or making incapable of movement; as, immobilization of the injured knee was necessary; the storm caused complete immobilization of the rescue team s>. Noun 1. devices and appliances for use in radiotherapy. Co-founders Michael Mailling and John Wright join the Axellis leadership team where their broad understanding of 3D data processing data processing or information processing, operations (e.g., handling, merging, sorting, and computing) performed upon data in accordance with strictly defined procedures, such as recording and summarizing the financial transactions of a , derived design and manufacturing in the healthcare sector will be invaluable as Axellis moves into its own production of medical devices and ancillary support systems designed for individual patients. The Axellis website is currently under construction. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion